MARKET IS CLOSED
Loading latest tickers...

Market Indices

S&P 500
$7,801.77
-0.22%
NASDAQ 100
$31,160.08
-0.21%
DOW JONES
$51,180.00
-0.66%
NASDAQ Composite
$27,538.69
-0.22%
RUSSELL 2000
$2,777.00
-1.29%
CBOE VIX
$15.08
+0.47%

Sector Heatmap

Technology-0.30%
Financials-0.48%
Healthcare+1.03%
Consumer Cycl-0.32%
Consumer Staples-0.12%
Energy-0.58%
Industrials-2.18%
Materials-1.51%
Real Estate-1.29%
Utilities-0.02%
Comm Services-0.35%

RIGL — Rigel Pharmaceuticals Inc. (New)

Nasdaq

Rigel Pharmaceuticals Inc. (New)

CompareBack to Screener
$47.99
+1.88(+4.08%)
O
45.64
H
48.15
L
45.22
V
229.26K
⏱️ End-of-day dataAs of Oct 7, 2026
OverviewStatisticsFinancialsHistorical DataOptionsDividend HistoryNewsChart

Chart

About RIGL

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateNov 29, 2000
Employees174
Stock ExchangeNasdaq
Ticker SymbolRIGL
Websitehttps://www.rigel.com

Key Financial Statistics

Market Cap$880.76M
P/E RatioN/A
Dividend YieldNone
EPSN/A
BetaN/A
52-Week Range$24.95 - $52.24
52-Week Avg Volume412.7K
VWAP$47.56
Transactions4,750
Total Recorded Bars6,500 days